Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The FRONTIER3 trial (NCT05306418) achieved its co-primary endpoints ...

Novo Nordisk is doing exceptionally well in the ... I highlight ziltivekimab, Mim8, amycretin, coramitug, and etavopivat, which, in my opinion, will not only be able to return the interest of ...

Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame, as ...

Shareholders may receive a hard copy of Novo Nordisk’s completed audited financial ... results evaluating safety profile and efficacy of Mim8 prophylaxis administered once every two weeks ...

Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER program will be disclosed at upcoming congresses and in publications in 2025 and 2026.

Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Elsewhere in the hemophilia space, Novo Nordisk earlier this month reported that its bispecific antibody Mim8 reduced bleeding events in pediatric patients. The pharma is preparing for regulatory ...

Novo Nordisk has been accepted back into the fold. Two years after suspending Novo, the Association of the British ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...